1 Optimal and worst examination strategies for COVID-19

2	
3	Onishi Tatsuki ^{a,b} , Honda Naoki ^{c,d,e} †, Yasunobu Igarashi ^{f,g} *
4	
5	^a Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University,
6	Yoshidakonoecho, Sakyo, Kyoto, Japan
7	^b Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan
8	^c Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University,
9	Higashihiroshima, Hiroshima, Japan
10	^d Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems
11	(ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan
12	^e Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho,
13	Sakyo, Kyoto, 606-8315, Japan
14	^f E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan
15	^g Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of
16	Technology, Nagoya, Aichi, Japan
17	
18	* Corresponding author
19	Yasunobu Igarashi
20	Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of
21	Technology
22	Gokiso-cho, Showa-ku, Nagoya, Aichi, 466-8555 Japan
23	Tel.: +81-52-735-5334
24	E-mail: yasunobu.igarashi@gmail.com
25	
26	† Co-corresponding author
27	Honda Naoki
28	Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University,
29	1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima, 739-8511 Japan
30	Tel.: +81-82-424-7336
31	E-mail: nhonda@hiroshima-u.ac.jp
32	
33	

34 Abstract

35 Coronavirus disease 2019 (COVID-19) is an emerging threat to the whole world, and every government is 36 seeking an optimal solution. However, none of them have succeeded, and they have only provided series of 37 natural experiments. Although simulation studies seem to be helpful, there is no model that addresses the 38 how much testing to be conducted to minimise the emerging infectious disease outbreaks. In this study, we 39 develop a testing susceptible, infectious, exposed, recovered, and dead (testing-SEIRD) model using two 40 discrete populations inside and outside hospitals. The populations that tested positive were isolated. Through 41 the simulations, we examined the infectious spread represented by the number of cumulative deaths, 42 hospitalisations, and positive tests, depending on examination strategies, testing characteristics, and 43 hospitalisation capacity. We found all-or-none responses of either expansion or extinction of the infectious 44 spreads, depending on the rates of follow-up and mass testing, which represent testing the people identified 45 as close contacts with infected patients using follow-up surveys and people with symptoms, respectively. We 46 also demonstrated that there were optimal and worst examination strategies, which were determined by the total resources and testing costs. The testing-SEIRD model is useful in making decisions on examination 4748 strategies for the emerging infectious disease outbreaks.

50 **1. Introduction**

51 Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. It has already spread worldwide [1,2]. So 52 far, 5.5 million people have been infected, and 350,000 people have died [3]. Owing to its high transmission 53 ability via aerosol, COVID-19 is an emerging concern in global health care. This is similar to influenza, 54 which annually leads to 300,000 to 600,000 deaths worldwide [4]. In addition, the fatality rate of COVID-19 55 is 3% - 4%, which is relatively higher than 1% for influenza [5], owing to lack of a specific radical treatment or vaccine. Even worse, the infectious period of COVID-19 is 20 days longer than the three days for 56 57 influenza [6], and COVID-19 causes multiple secondary infections. Therefore, testing for COVID-19 is important for the early detection of asymptomatic infected people and prevention of secondary infections. 58 However, the effect of testing policy on the spread or reduction of COVID-19 infection dynamics remains 59 elusive. 60

61 Currently, there is a social problem because medical resources in hospitals are largely consumed by 62 treatments for COVID-19 patients. Symptomatic treatments for patients with pneumonia require both beds 63 and healthcare providers; however, there are limited equipment such as intensive care units, ventilators, 64 haemodialysis, and extracorporeal membrane oxygenators. If symptoms develop, intensive care units are necessary. Consequently, hospital stay for COVID-19 has become exceedingly long, indicating a median of 65 66 29 days [7–11]. The imbalance between the supply and demand of medical resources causes the increase in the number of deaths after infection [11,12]. Therefore, each country must control the balance between the 67 68 medical supply and demand from people who visit hospitals and need testing for COVID-19.

69 There is a controversy between two extreme policies to balance the medical supply and demand: 70 "mass testing policy" and "no testing policy" [13]. The mass testing policy claims that all people must be 71 tested for public health, regardless of the symptoms. As the director of WHO, Tedros said, "test, test, test," in 72 an opening remark on 16 March 2020 [14]. The WHO and some researchers follow the mass testing policy 73 [15,16]. This policy is based on the assumption that the testing accuracy is sufficiently high, and when more testing is conducted, the total number of deaths is reduced. Contrary to the mass testing policy, no testing 74 policy claims that testing must be limited to people with symptoms. This indicates that it does not 75 76 recommend testing for people with asymptomatic or mild symptoms or having no contact with infectious 77 people. This policy underlies the idea that individuals are unable to expect a benefit from mass testing in the 78 absence of the specific treatment. This was expressed by the committee for the emerging and re-emerging 79 infectious disease in the Japanese society of paediatrics on 13th March 2020 [17]. Although there is 80 discordance in these two policies with different beliefs, these two policies agree with testing on people with 81 symptoms. They also disagree on the extent of the population tested.

Essentially, society demands the minimisation of the number of deaths [18]. Thus, we need to explore the most practical policy by integrating these extreme policies. Consequently, we must notice the advantages and disadvantages of testing. The proof of testing is simply that it can detect infected asymptomatic people. Thus, testing is helpful to save lives before developing severe symptoms and can prevent further spread of the infection. The reason for testing is that testing itself is not perfect, and it is

87 inevitable from false positives and negatives. If uninfected people are evaluated as positive by testing (i.e., 88 false positives are hospitalised), the people are subject to the risk of high infection from infected patients in 89 the hospital.

The examination has two strategies: follow-up testing-dominant strategies which follow the exposed 90 91 population and mass testing-dominant strategy which considers the infected population by random testing. 92 However, the extent to which the follow-up and mass testing should be conducted to minimise deaths, 93 hospitalisations, and positive tests is yet to be considered. Therefore, we need to predict the infection 94 dynamics affected by the examination strategies, or the rate of follow-up and mass testing. We also noticed 95 that the effect of testing on the overall infection population dynamics has not been adequately considered. 96 Therefore, we need to predict the infection dynamics affected by the amount of testing by considering the 97 testing characteristics (i.e., sensitivity and specificity) to quantify their positive and negative impacts.

In this study, we develop a testing-SEIRD model by introducing a hospitalised subpopulation, examination strategy, and testing characteristics. Through simulations, we examined the impact of the examination strategies and testing characteristics on the balance between medical supply and demand. We found that there are optimal and worst strategies and highlighted which examination strategy is preferred,

102 based on the testing characteristics.

2. Model 104

105 To examine the effect of testing on the infection population dynamics, we developed a new model by

- introducing a hospitalised subpopulation, examination strategy, and testing characteristics into the classical 106
- SEIRD model. In general, the SEIRD model is described by the subpopulation dynamics of susceptible, 107
- 108exposed, infectious, recovered, and dead people (Fig. 1A) as:

$$\frac{dS}{dt} = -\frac{bIS}{N}, \#(2.1)$$
$$\frac{dE}{dt} = \frac{bIS}{N} - gE, \#(2.2)$$
$$\frac{dI}{dt} = gE - (r+d)I, \#(2.3)$$
$$\frac{dR}{dt} = rI, \#(2.4)$$
$$\frac{dD}{dt} = dI, \#(2.5),$$

109 where S, E, I, R, and D indicate the populations of susceptible, exposed, infectious, recovered, and dead people, respectively. N indicates the total population, that is, N=S+E+I+R. b indicates the exposure rate, 110 which reflects the level of social activity; g, r, and d indicate the transition rates among the subpopulations. 111 112 For this model, it is assumed that the recovered populations acquire permanent immunity, indicating that 113 they will never be infected.

114 Regarding the testing-SEIRD model, we incorporated the testing characteristics and examination 115 strategy into the classical SEIRD model by dividing the population into outside and inside of the hospitals 116 (Fig. 1B). The dynamics of the population outside the hospitals are described by:

10

$$\frac{dS_o}{dt} = -\frac{bI_oS_o}{N_o} + uE_o - aS_h, \#(2.6)$$
$$\frac{dE_o}{dt} = -\frac{bI_oS_o}{N_o} - (u+g)E_o - f(1-Sp)E_oH(C-N_h), \#(2.7)$$
$$\frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_oH(C-N_h), \#(2.8)$$
$$\frac{dR_o}{dt} = r_oI_o, \#(2.9)$$
$$\frac{dD_o}{dt} = d_oI_o, \#(2.10),$$

117 and those inside hospitals were described by:

$$\frac{dS_h}{dt} = -\frac{bI_h S_h}{N_h} + uE_h + aS_h, \#(2.11)$$

$$\frac{dE_h}{dt} = \frac{bI_h S_h}{N_h} - (u+g)E_h + f(1-Sp)E_oH(C-N_h), \#(2.12)$$
$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_oH(C-N_h), \#(2.13)$$
$$\frac{dR_h}{dt} = r_hI_h, \#(2.14)$$
$$\frac{dD_h}{dt} = d_hI_h, \#(2.15).$$

 X_o and X_h indicate each population outside and inside the hospitals ($X \in \{S, E, I, R, D, N\}$). N_o and N_h 118 indicate the total populations outside and inside hospitals, respectively (i.e., $N_o = S_o + E_o + I_o + R_h$ and 119 $N_h = S_h + E_h + I_h$; a indicates the rate of discharge of S_h from hospital to the outside; u and g indicate the non-120 121 infection and infection rates, respectively; and C indicates the capacity of hospitals. We assumed that these 122parameters are determined by the nature of the disease; thus, they are independent of inside and outside 123 hospitals. r_i and d_i ($j \in \{o, h\}$) indicate the recovery and death rates from infected, respectively, where $r_o < r_h$, 124 and $d_h < d_o$. f and m indicate the rates of follow-up and mass testing, corresponding to the extent to which 125health centres follow exposed populations and take-up infected populations having symptoms, respectively. 126 Sp and Se indicate specificity and sensitivity, respectively, as testing characteristics. Mass testing in this 127 model is a mass test for individuals who claim symptoms. This model is a generalised version of the classic 128 SEIRD model. If u=0, our model is equivalent to the classical SEIRD model. The hospitalisation capacity 129 was introduced by the sigmoid function $H(x) = 1/(1 + \exp(x))$. The parameter values and initial conditions are listed in Table 1 and discussed in the Materials and Methods section. 130

132 **3. Results**

133 We first examine the basic behaviour of the testing-SEIRD model by simulation as shown in Fig. 2. Similar to the classical SEIRD model, infection largely expanded, and the infectious population (I_h and I_o) transiently 134increased in response to the occurrence of infectious people. Susceptible populations (S_h and S_o) gradually 135decreased and shifted into recovered populations (R_h and R_o) through the exposed (E_h and E_o) and infectious 136 137 $(I_{\rm h} \text{ and } I_{\rm o})$ states. During this process, the number of dead cells increases gradually as shown in Fig. 2A. The hospitalised population increase, plateau at the capacity of hospitalisations within the period of infection 138 overshoot, and decrease by the hospital discharge (Fig. 2B). The outside population decrease by 139140 hospitalisations through testing and switch to a constant decrease, whereas the hospitalised population 141 reaches its capacity and increases by the hospital discharge (Fig. 2B). Moreover, the outside and hospitalised 142 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead) 143 (Fig. 2C and D). Daily reports of positive tests and deaths transiently increase with different peak timings, 144 and the peak of positive tests precedes that of deaths (Fig. 2E). Reproduction numbers (see Materials and 145 Methods) outside hospitals RN_{a} switch from greater than one to less than one around the peak timing of 146infectious populations outside (Fig. 2F). On the contrary, reproduction numbers inside hospitals RN_h are less 147 than one. This indicates that the infectious population in hospitals increases owing to supply from the 148 outside; however, it is not because of the infectious spread in hospitals. The testing-SEIRD model recapitulates basic infection dynamics of the total population as observed in the classical SEIRD model (Fig. 149 2A), and enables us to examine the effect of the examination strategy and testing characteristics with 150 151 different populations inside and outside hospitals.

To investigate the impact of hospitalisation capacity on infection dynamics, such as daily reports of positive tests, hospitalisations, and deaths, we simulate the testing-SEIRD model with various capacities (Fig. 3A to C). We observe that as the capacity increases, the maximum positive tests, maximum hospitalisations, and cumulative deaths linearly decrease, increase, and decrease, respectively, and they all plateau at approximately 30% capacity (Fig. 3D to F). We have also examined their peak timings and have observe that they change nonlinearly, with certain time window ranges (Fig. 3G–I). These results suggest that the change in capacity has a large effect on the level of spread of the disease; nonetheless, it has a small effect on timing.

To illustrate the impact of the examination strategy on infectious outcomes, we examined the cumulative deaths, maximum number of positive tests and hospitalisations, varying follow-up and mass testing rates. The infectious spread shows an all-or-none response depending on the testing strategy (red and blue regions in Fig. 4). Sensitivity analyses confirmed that such a profile was robustly maintained independent of the model parameters (Fig. S1 and S2).

The number of cumulative deaths is almost constant with a small amount of both the follow-up and mass testing (red region in upper panel of Fig. 4A); nonetheless, the combination of follow-up and mass testing cooperatively suppresses the infectious spread (blue region in the upper panel of Fig. 4A). We also realize that the maximum number of hospitalisations is immediately saturated by either the follow-up or mass testing because of the limited hospitalisation capacity (upper panel in Fig. 4B). The maximum number

of positive tests increases more efficiently with the follow-up testing rate compared to the mass testing rate(upper panel in Fig. 4C).

Subsequently, realistic scenarios were considered by adapting the limited resource L. Practically, we cannot freely control the follow-up and mass testing rates because of the limited clinical resources for both the follow-up and mass testing. Thus, it is necessary to determine the amount of resources allocated to the follow-up and mass testing. Here, we consider all the possible decisions subject to the limited resource L as:

$$L = c_f f + c_m m, \#(3.1)$$

where c_f and c_m indicate the costs for follow-up and mass testing, respectively; f and m are reflected by the decisions on how much follow-up and mass testing are conducted. Considering different L, c_f , and c_m , based on the disease, economic and technological situations of each country, we depicted three lines. We observe that the worst decisions (i.e., the choice of f and m) drastically varied depending on the situation (lower

panels of Fig. 4).

180 Regarding the high resource and low ratio of the cost of follow-up testing to that of the mass testing 181 cost, the number of cumulative deaths abruptly increases more than 90% compared to the resource fraction 182 assigned to mass testing (green line in Fig. 4A). This indicates that the mass testing dominant testing is the 183 worst strategy for minimising the cumulative deaths. On the contrary, considering low resource and high ratio of follow-up cost to mass testing cost, the number of cumulative deaths abruptly decreases at the 184 185 resource fraction of 20% to 30 % (blue line in Fig. 4A) assigned to mass testing. Contrary to the previous 186 case, this result suggests that follow-up-dominant testing is the worst strategy. Regarding the intermediate 187 situation between the two cases above, the simulation showed a U-shape with the resource fraction assigned to mass testing ranging from approximately 10 to 80 % (orange line in Fig. 4A). This indicates that both 188 189 follow-up and mass-dominant testing are strategies to avoid, whereas the optimal strategy is a combination 190 of the follow-up and mass testing. The choice of f and m also changed in the profiles of maximum 191 hospitalisations and positive reports (Fig. 4B and C). Taken together, the optimal strategy for each 192 country/region should be sought with the resources considered.

Moreover, we examined how the three variables (i.e., the number of cumulative deaths, 193194 hospitalisations, and positive tests) are affected by the testing characteristics (i.e., sensitivity and specificity). 195 We conducted sensitivity analyses for Se and Sp with values from zero to four with 0.01 increments. We 196 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted 197 along the x-axis (Fig. 5). The equations (2.7, 2.8, 2.12, and 2.13) reveal that sensitivity and one-specificity 198 essentially play the same roles in the follow-up and mass testing. The sensitivity and specificity of the test 199 are not modifiable, whereas the testing strategy can be arbitrary. If the sensitivity is low, an increase in the 200 mass testing rate can lead to the same infectious result with high sensitivity. On the contrary, if the specificity 201 is low, a decrease in the follow-up testing rate can lead to the same infectious result with high specificity. 202 Therefore, we must manage the optimal testing strategy based on the unmodifiable testing sensitivity and 203 specificity.

We have investigated how the infection is expanded based on the testing strategy. However, this is the point of view of a perfect observer who knows the exact time course of the latent populations. Practically,

we are unable to know all the model variables, such as exposed and infectious populations inside and outside

- 207 hospitals; nonetheless, we can merely monitor positive reports by follow-up and mass testing. In this study,
- 208 we verify whether these two kinds of positive reports reflect the latent infectious population, which is the
- 209 most resource-consuming and challenging social issue. Using regression analysis (see Materials and
- 210 Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of
- follow-up and mass testing (Fig. 6A to C). These results suggest that the infectious population is not simply
- 212 proportional to the sum of positive reports of follow-up and mass testing; nevertheless, they are proportional
- to their weighted sum (Fig. 6D). There are cases in which either weights can be negative, depending on the
- 214 model parameters. We found that the weight for positive reports of follow-up testing was negative with high
- 215 positive predictive values. This is because the negative weight of P_f acts in a repressive manner to estimate
- the latent number of infectious people, reflecting a low positive predictive value (Fig. 6D).

218 **4.Discussion**

We develop a testing-SEIRD model to consider two discrete populations inside and outside hospitals, impact of examination strategy (follow-up testing [f], and mass testing [m]), and testing characteristics (sensitivity [Se] and specificity [Sp]) on three variables (i.e., the number of maximum positive tests, maximum hospitalisations, and cumulative deaths (Fig. 1)). We also demonstrate that the optimal and worst examination strategies are subject to limited testing resources (Fig. 4). In addition, we highlight the possibility that the infectious population can be predicted by a weighted sum of positive reports from followup and mass testing (Fig. 6).

226

227 (a) Comparison with previous models.

228 There are several models of infectious dynamics, such as SIR [19], SEIRD models, and their alternatives, 229 which have been widely used for policy making through model simulation [1,4,20-26]. However, some of 230 the previous models do not include the hospital compartment, [20,25,27–29] and other models, even with 231 hospital compartments, do not consider the examination strategy and testing characteristics [22,30]. They 232 cannot address how the examination strategy and testing characteristics affect infectious population 233 dynamics, such as clinical and social overshoot. Consequently, we develop the testing-SEIRD model by 234 introducing new factors: the hospital compartment, examination strategy, and testing characteristics to the 235 previous SEIRD model (Fig. 2 and 3). The testing-SEIRD model generalises the classical SEIRD model, and 236 it can be equivalent to the classical SEIRD model if the examination strategy is removed (f=0, m=0).

237

238 **(b) Model prediction**

239 This model has three advantages. First, the testing-SEIRD model provides the best examination strategy for 240 situations. The model provided heatmaps of the number of the three variables in the space of the examination 241 strategy (Fig. 4). This map indicates the best direction as shown in the blue region in Fig. 4. This corresponds 242 to the settling of infections using the shortest path. Second, the testing-SEIRD model can predict the optimal 243 and worst strategies, considering the limited resources and ratios for the testing costs (Fig. 4). Because the 244 total resource and testing costs depend on countries, our model offers the best examination strategy unique to 245 each country. Third, the testing-SEIRD model demonstrate that the latent number of infectious population 246can be predicted from daily positive reports of the follow-up and mass testing (Fig. 6).

247

248 (c) Validity of model components

Here, we discuss the validity of the model components, which previous models do not have. First, we focus on the transition from E_o to E_h (Fig. 1). We assume that the hospitalisation of the exposed population is induced by the follow-up testing. Populations that are just exposed before developing symptoms do not take the tests themselves. They test only when urged by the follow-up. Second, related to the transition from I_o to I_h , we assume that the hospitalisation of the infectious population is induced by the mass testing, which is defined as a person with symptoms. Considering our model, we address the rate of mass testing as a

modifiable parameter because the rate depends on the volume of the tests, such as polymerase chain reaction (PCR) and the degree of social penalty if it is positive. Third, we consider the transition from E_o to S_o and E_h to S_h . Regarding our model, all the exposed populations are not necessarily infected and some return

susceptible compared to the previous models which assume that all the exposed populations are destined to

- be infected [20,22,24,25,27–33]. Consistent with our model, it is well known that some exposed populations
- return to susceptible populations without developing symptoms.
- 261

262 (d) Future studies

263 Considering the future perspectives of our model, first, our testing-SEIRD model simulates only a single 264 peak time course of infection. However, we observed multiple peaks of COVID-19 infection in many 265 countries [34]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological 266 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all the 267 populations are homogeneous and do not address stratification based on attributes such as gender, age, social 268activities, and comorbidities [35,36]. A future study should consider this perspective. Finally, our model does 269not include the effects of vaccination. We are currently fighting the spread of COVID-19 using messenger 270 RNA (mRNA) vaccines. It seems we are getting successful results; however, we do not know the duration of 271 the effect of the vaccinations and its robustness against mutants [34,37,38]. Therefore, the tag-of-war model 272 between vaccines and virus evolution remains elusive.

274 **5.Materials and Methods**

275 (a) Parameter set

276 The parameters and initial conditions of the simulation are listed in Table 1A. The total population N was set 277 to 1,000,000 according to the United Nations Statistical Papers: The World's Cities in 2018, which 278mentioned that one in five people worldwide lives in a city with more than one million inhabitants and the 279 median value of inhabitants is between 500,000 and one million [39]. Sensitivity Se and specificity Sp were both set to 0.7, which correspond to those of the PCR for detecting COVID-19 (Table 1B) [20,31,40-42]. 280 The values of b, g, r_h , r_o , and d_h are based on previous reports (Table 1C) [3,21–26,28–30,32]. The sum of u 281 282and g is the inverse of the incubation period during the exposed state, which is reported to be five days 283(Table 1C) [23–25,33,41,43,44]. The sum of r and d is the inverse of the infectious period during the infectious state, which is reported to be ten days (Table 1D) [23,24,27,41,43]. 284

285

286 **(b) Definitions of reproduction numbers**

Considering Fig. 2, we computed the time courses of reproduction numbers inside and outside hospitals: RN_h and RN_o .

$$RN_{h} = \frac{1}{r_{h} + d_{h}} \cdot \frac{bS_{h}}{S_{h} + E_{h} + I_{h}} \cdot \frac{g}{u + g}, \#(5.1)$$
$$RN_{o} = \frac{1}{r_{o} + d_{o}} \cdot \frac{bS_{o}}{S_{o} + E_{o} + I_{o} + R_{o} + R_{h}} \cdot \frac{g}{u + g}. \#(5.2)$$

Here, the first, second, and third factors in these equations indicate the average infectious period, infection rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction number in the classical SEIRD model is defined in previous studies [1,4,20–26] as:

$$RN = \frac{1}{r+d} \cdot \frac{bS}{S+E+I+R} \cdot \#(5.3)$$

292

294 Acknowledgments

295 We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concept of

296 clinical NNT. We also thank Prof. Hiroshi Nishiura for providing the fundamental knowledge of infectious disease

297 modelling by organising a summer boot camp in 2014.

298

299 Funding

300 This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and

- 301 Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Young
- 302 Scientists (B) (16K16147 and 19H04776 to H.N.) from the Japan Society for the Promotion of Science (JSPS).

303

304 Ethics

305 Any human or animal subjects are not involved in this manuscript.

306

307 Data Availability

308 All relevant data are within the study and its supporting information files.

309

Code Availability

311 https://github.com/bougtoir/testing-SEIRD

312

313 Author Contributions

314 O.T. and Y.I. conceived of the initial ideas. O.T. developed and implemented the method, processed, and analysed

the data, and wrote the initial draft of the manuscript. H.N. edited the initial draft of the manuscript and reviewed

the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

317

318 **Competing Interests**

319 The authors declare no competing interests.

321 **References**

322 1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. 2020 COVID-19 infection: Origin, transmission, and characteristics 323 of human coronaviruses. Journal of Advanced Research 24, 91-98. (doi:10.1016/j.jare.2020.03.005) 324 2. Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari H. 2020 Epidemiological and 325 Clinical Aspects of COVID-19; a Nar- rative Review. Clinical Aspects of COVID 8, 41. 326 3. Johns Hopkins Coronavirus Resource Center. In press. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. See 327 https://coronavirus.jhu.edu/map.html (accessed on 21 May 2020). 328 4. Roguski KM et al. 2019 Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The 329 Lancet 391, 1285–1300. (doi:10.1016/S0140-6736(17)33293-2.Estimates) 330 5. World health organization. In press. Coronavirus disease 2019 (COVID-19) Situation Report – 46. 331 6. Zhou F et al. 2020 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a 332 retrospective cohort study. The Lancet 395, 1054-1062. (doi:10.1016/S0140-6736(20)30566-3) 333 7. Giwa AL, Desai A, Duca A. 2020 Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency 334 clinicians. Emergency medicine practice 22, 1-28. 335 8. Zhu S, Guo X, Geary K, Zhang D. 2020 Emerging Therapeutic Strategies for COVID-19 Patients. Discoveries 8, e105. 336 (doi:10.15190/d.2020.2) 3379. Stratton SJ. 2020 COVID-19: Not a Simple Public Health Emergency. Prehospital and Disaster Medicine 35, 119. 338 (doi:10.1017/S1049023X2000031X) 339 10. Swiss Academy Of Medical Sciences. 2020 COVID-19 pandemic: triage for intensive-care treatment under resource scarcity. 340 Swiss medical weekly 150, w20229. (doi:10.4414/smw.2020.20229) 341 11. The Japanese society of intensive care medicine. In press. COVID19 Clinical report 20200322 v3. 342 12. ANZICS. In press. ANZICS COVID-19 Guidelines Version 2 - ANZICS. See https://www.anzics.com.au/anzics-covid-19-343 guidelines-version-2/ (accessed on 21 May 2020). 344 Our world in Data. In press. GitHub - owid/covid-19-data: Data on COVID-19 (coronavirus) cases, deaths, hospitalizations, 13. tests • All countries • Updated daily by Our World in Data. See https://github.com/owid/covid-19-data (accessed on 21 May 345 346 2020). 347 14. World health organization. In press. WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 348 March 2020. See https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-349 media-briefing-on-covid-19---16-march-2020 (accessed on 21 May 2020). 350 15. Godlee F. 2020 The burning building. The BMJ 368, 2020. (doi:10.1136/bmj.m1101) 351 16. Peto J. 2020 Covid-19 mass testing facilities could end the epidemic rapidly. The BMJ 368, 110110. 352(doi:10.1136/bmj.m1163) 353 17. COVID-19 of Thought Japanese society pediatrics. In press. on testing. See 354 http://www.jpeds.or.jp/modules/activity/index.php?content_id=329 (accessed on 21 May 2020). 355 Joebges S, Biller-Andorno N. 2020 Ethics guidelines on COVID-19 triage - An emerging international consensus. Critical 18. 356 Care 24, 1–5. (doi:10.1186/s13054-020-02927-1) 357 19. Phelan. 2018 Mathematical models to characterize early epidemic growth: A Review Gerardo. Physiology & behavior 176,

358		139–148. (doi:10.1016/j.plrev.2016.07.005.Mathematical)
359	20.	Fang Y, Nie Y, Penny M. 2020 Transmission dynamics of the COVID-19 outbreak and effectiveness of government
360		interventions: A data-driven analysis. Journal of medical virology (doi:10.1002/jmv.25750)
361	21.	Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. 2020 An updated estimation of the risk of transmission of the novel
362		coronavirus (2019-nCov). Infectious Disease Modelling 5, 248-255. (doi:10.1016/j.idm.2020.02.001)
363	22.	Kucharski AJ et al. 2020 Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The
364		Lancet Infectious Diseases 20, 553-558. (doi:10.1016/S1473-3099(20)30144-4)
365	23.	Backer J, Klinkenberg D, Wallinga J. 2020 The incubation period of 2019-nCoV infections among travellers from Wuhan,
366		China. Eurosurveillance, 1-6. (doi:10.1101/2020.01.27.20018986)
367	24.	Bi Q et al. 2020 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen,
368		China: a retrospective cohort study. The Lancet Infectious Diseases 20, 911-919. (doi:10.1016/S1473-3099(20)30287-5)
369	25.	Kuniya T. 2020 Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. Journal of clinical medicine 9.
370		(doi:10.3390/jcm9030789)
371	26.	Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. 2020
372		Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A
373		statistical analysis of publicly available case data. Journal of Clinical Medicine 9, 538. (doi:10.1101/2020.01.26.20018754)
374	27.	Joseph TW, Leung K, Leung GM. 2020 Nowcasting and forecasting the potential domestic and international spread of the
375		2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet, 689–697.
376	28.	Iwata K, Miyakoshi C. 2020 A Simulation on Potential Secondary Spread of Novel Coronavirus in an Exported Country
377		Using a Stochastic Epidemic SEIR Model. Journal of Clinical Medicine 9, 944. (doi:10.3390/jcm9040944)
378	29.	Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. 2021 Tracking Reproductivity of COVID-19 Epidemic in China with
379		Varying Coefficient SIR Model. Journal of Data Science 18, 455–472. (doi:10.6339/jds.202007_18(3).0010)
380	30.	Rocklöv J, Sjödin H, Wilder-Smith A. 2021 COVID-19 outbreak on the diamond princess cruise ship: Estimating the
381		epidemic potential and effectiveness of public health countermeasures. Journal of Travel Medicine 27, 1-7.
382		(doi:10.1093/JTM/TAAA030)
383	31.	Lin L et al. 2020 Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT.
384		Applied Intelligence 2019 , 1–5.
385	32.	Roda WC, Varughese MB, Han D, Li MY. 2020 Why is it difficult to accurately predict the COVID-19 epidemic? Infectious
386		Disease Modelling 5, 271–281. (doi:10.1016/j.idm.2020.03.001)
387	33.	World health organization. In press. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).
388		See https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
389		(accessed on 21 May 2020).
390	34.	GISAID. In press. GISAID - Initiative. See https://www.gisaid.org/ (accessed on 9 May 2021).
391	35.	Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. 2020 A Primer on COVID-19 Mathematical Models.
392		Obesity 28, 1375–1377. (doi:10.1002/oby.22881)
393	36.	Shahid Z et al. 2020 COVID-19 and Older Adults: What We Know. Journal of the American Geriatrics Society 68, 926–929.
394		(doi:10.1111/jgs.16472)
395	37.	Sharp TM et al. 2021 Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

396		New England Journal of Medicine 384, 2257–2259. (doi:10.1056/nejmc2023298)									
397	38.	Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. 2020 Assessment of protection against reinfection with SARS-									
398		CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet,									
399		19–21.									
400	39.	United Nations. 2018 The World's Cities in 2018: Data Booklet. (doi:10.18356/C93F4DC6-EN)									
401	40.	Tao A, Zhenlu Y, Hongyan H, Chenao Z, Chong C, Wenzhi L, Qian T, Ziyong S, Liming X. 2014 Correlation of Chest CT									
402		and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 80, 1-8.									
403		(doi:10.14358/PERS.80.2.000)									
404	41.	Long C et al. 2020 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? European Journal of Radiology									
405	42.	Lai S et al. 2021 Effect of non-pharmaceutical interventions to contain COVID-19 in China. Natutre 585, 410-413.									
406		(doi:10.1038/s41586-020-2293-x.Effect)									
407	43.	Fang J, Lau CKM, Lu Z, Wu W, Zhu L. 2019 Natural disasters, climate change, and their impact on inclusive wealth in G20									
408		countries. Environmental Science and Pollution Research 26, 1455–1463. (doi:10.1007/s11356-018-3634-2)44.									
409		Ahmad N, Derrible S, Managi S. 2018 A network-based frequency analysis of Inclusive Wealth to track sustainable									
410		development in world countries. Journal of Environmental Management 218, 348-354.									
411		(doi:10.1016/j.jenvman.2018.04.070)									
412											



413

414 Figure 1: Classical SEIRD and testing-SEIRD models

415 (A) Classical SEIRD model: Susceptible population 'S' is exposed by infectious population 'l' at a rate 416 proportional to the fraction of the infectious population. The exposed population 'E' become infectious 'I'. The 417 infected population finally recovers 'R' or become dead 'D'. (B) Testing-SEIRD model: The population is 418 divided into two subpopulations; inside and outside hospitals. The exposed 'E_o' and infectious population 419 outside 'lo' are hospitalised if evaluated as positive by testing. Susceptible population 'Sh' is left from the 420 hospitals. The black lines indicate the transitions of populations, regardless of capacity effect. The blue lines 421indicate the transitions of the populations, considering the capacity effect. Transitions from both (E_o) to (E_h) 422 and (I_o) to (I_h) are determined as hospitalised.



424

425 Figure 2: Changes in components over time in the testing-SEIRD model

Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B)
Populations inside and outside hospitals and dead populations, irrespective of infectious states; (C)
Populations of all infectious states inside hospitals; (D) Populations of all infectious states outside hospitals;
(E) Daily reports of positive tests, hospitalisations, and deaths; (F) Time-courses of reproduction numbers
inside and outside hospitals, as described in Materials and Methods section.



432

433 Figure 3: Impact of hospitalisations capacity on the three variables

Time courses of (A) Daily reports of positive tests; (B) Daily reports of hospitalisations; (C) Daily reports of deaths with varying hospitalisation capacity. C/N indicates the capacity normalised to the total population.

436 Hospitalisation capacity dependencies of (D) Maximum positive reports; (E) Maximum hospitalisations; (F)

437 Cumulative deaths. Hospitalisation capacity-dependencies of (G) Peaks of daily reports of positive tests; (H)

438 Peaks of hospitalisations; (I) Peaks of daily deaths.



440

441 Figure 4: Infectious spread based on the examination strategy

The upper panels represent the number of (A) cumulative deaths, (B) maximum hospitalisations, and (C) maximum daily positive tests depending on the rates of follow-up and mass testing. The three lines in these heatmaps represent the possible testing strategies subject to different total resources for testing with different ratios for the testing costs. The lower panels represent the numbers along the three lines in the heatmap.



448

449 Figure 5: Infectious spread based on the testing properties

- 450 Number of (A) Cumulative deaths, (B) Maximum hospitalisations, and (C) Maximum daily positive tests
- 451 based on the sensitivity and specificity of the testing.



452



(A-C) The Green and orange lines indicate the simulated and predicted infectious populations (I_h and I_o) with different examination strategies. The infectious populations are estimated by the linear regression *as* w_fP_f + w_mP_m where w_f and w_m indicate the weights and P_f and P_m indicate the daily positive reports of follow-up and mass testing, namely f(1-Sp) and mSe, respectively. The weights are estimated by the least square method. (D) The estimated weights for P_f and P_m are plotted, considering various combinations of ratios of the followup cost to the mass testing cost (P_f/P_m).

А		С							
Variable	Value	Reference	Model	b	g	ľh	ro	dh	do
Sh,Eh,Ih	1	Fang ²⁰	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a
10	97	Tang ²¹	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a
S.	999900	Kucharski ²²	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a
Eo,Rh,Ro,Dh,Do	0	Backer ²³	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a
		Bi Q ²⁴	n/a	n/a	n/a	n/a	n/a	n/a	n/a
		Kuniya ²⁵	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a
Parameter	Value	Linton ²⁶	n/a	n/a	0.2	n/a	n/a	n/a	n/a
Se	0.7	Iwata ²⁸	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a
Sp	0.7	Sun H ²⁹	vSIR	n/a	n/a	0.1	n/a	n/a	n/a
f	0.05	Docklöu ³⁰	SEID	0.4 o 4 or 0.12 o 4+	0.2	n/a	n/o	n/o	n/a
m	0.01	RUCKIOV	JLIK	0.4 8-4 01 0.12 8-4	0.2	11/d	n/a	n/a	n/a
Ь	1	Roda ³²	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a
u	0.04								
g	0.10								
111	0.095			D	Reference	Incubation period		Infectious period	
dh	0.007				Kucharski ²²	5.2		2.9	_
do	0.01			Backer ²³		6.5		n/a	
					Bi ²⁴	48		1.5	
D					Wu ²⁷	6.1		2.3	
B Mod	e of test	Se Sp	Sp			5.1		10	
	CT 0.98 ²⁰ , 0.97 ^{31,40} , 0.929 t	0.828 to 0.96 ⁴¹		ROCKIOV	5		10		
	01	0.8 to 0.941,0.97242).972 ⁴² 0.828 10 0.90		Li ³¹			2.3	
F	PCR	0.71 ²⁰ ,0.846 ⁴²	n/a	WH	IO-China Joint ³³	5.5		n/a	

461

462 Table 1: Variables and parameters in previous reports

(A) Initial values for variables and parameters and (B) Reported sensitivity and specificity of PCR and CT for detecting COVID-19. Cells expressed as n/a indicate that we cannot find the (C) reported transition parameters with models. Values with † are calculated from the original values for comparison. All the values have dimensions of [one/day]. We cannot find values or models for the cells expressed as n/a. The values with † equal original values divided by the total population involved. (D) Reported incubation period and infectious period. All values have dimensions of [day].



472 Figure S1: Sensitivity analyses of parameters *b* and *m* on the number of cumulative deaths

- 473 Simulations were performed with different values of *b* and *m*.
- 474



Figure S2: Sensitivity analyses of parameter a on the number of cumulative deaths

Simulations were performed with different values of a.